{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T13:39:46Z","timestamp":1785332386270,"version":"3.55.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T00:00:00Z","timestamp":1692316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T00:00:00Z","timestamp":1692316800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003542","name":"Ministerium f\u00fcr Wissenschaft, Forschung und Kunst Baden-W\u00fcrttemberg","doi-asserted-by":"publisher","award":["Sonderf\u00f6rdermassnahme COVID-19, T\u00dc17"],"award-info":[{"award-number":["Sonderf\u00f6rdermassnahme COVID-19, T\u00dc17"]}],"id":[{"id":"10.13039\/501100003542","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["WA 4608\/1-2"],"award-info":[{"award-number":["WA 4608\/1-2"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["EXC2180 390900677"],"award-info":[{"award-number":["EXC2180 390900677"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008658","name":"Deutsches Krebsforschungszentrum","doi-asserted-by":"publisher","award":["DKTK"],"award-info":[{"award-number":["DKTK"]}],"id":[{"id":"10.13039\/100008658","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>T-cell immunity is central for control of COVID-19, particularly in patients incapable of mounting antibody\u00a0responses. CoVac-1 is a peptide-based T-cell activator composed of SARS-CoV-2 epitopes with documented favorable safety profile and efficacy in terms of SARS-CoV-2-specific T-cell response. We here report a Phase I\/II open-label trial (NCT04954469) in 54 patients with congenital or acquired B-cell deficiency receiving one subcutaneous CoVac-1 dose. Immunogenicity in terms of CoVac-1-induced T-cell responses and safety are the primary and secondary endpoints, respectively. No serious or grade 4 CoVac-1-related adverse events have been observed. Expected local granuloma formation has been observed in 94% of study subjects, whereas systemic reactogenicity has been mild or absent. SARS-CoV-2-specific T-cell responses have been induced in 86% of patients and are directed to multiple CoVac-1 peptides, not affected by any current Omicron variants and mediated by multifunctional T-helper 1 CD4<jats:sup>+<\/jats:sup> T cells. CoVac-1-induced T-cell responses have exceeded those directed to the spike protein after mRNA-based vaccination of B-cell deficient patients and immunocompetent COVID-19 convalescents with and without seroconversion. Overall, our data show that CoVac-1 induces broad and potent T-cell responses in patients with B-cell\/antibody deficiency with a favorable safety profile, which warrants advancement to pivotal Phase III safety and efficacy evaluation. ClinicalTrials.gov identifier NCT04954469.<\/jats:p>","DOI":"10.1038\/s41467-023-40758-0","type":"journal-article","created":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T17:01:55Z","timestamp":1692378115000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Phase I\/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7305-8620","authenticated-orcid":false,"given":"Jonas S.","family":"Heitmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Tandler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maddalena","family":"Marconato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8504-8481","authenticated-orcid":false,"given":"Annika","family":"Nelde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timorshah","family":"Habibzada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne M.","family":"Rittig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian M.","family":"Tegeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2197-8740","authenticated-orcid":false,"given":"Yacine","family":"Maringer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon U.","family":"Jaeger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Denk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Richter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melek T.","family":"Oezbek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl-Heinz","family":"Wiesm\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3731-2385","authenticated-orcid":false,"given":"Jens","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Rieth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8185-140X","authenticated-orcid":false,"given":"Marcel","family":"Wacker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4271-1498","authenticated-orcid":false,"given":"Sarah M.","family":"Schroeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9465-0175","authenticated-orcid":false,"given":"Naomi","family":"Hoenisch Gravel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5923-1343","authenticated-orcid":false,"given":"Jonas","family":"Scheid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2920-3894","authenticated-orcid":false,"given":"Melanie","family":"M\u00e4rklin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika","family":"Henrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Klimovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim L.","family":"Clar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Lutz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Holzmayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5718-1530","authenticated-orcid":false,"given":"Sebastian","family":"H\u00f6rber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Peter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Meisner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imma","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2513-1317","authenticated-orcid":false,"given":"Markus W.","family":"L\u00f6ffler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline Anna","family":"Peuker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3976-9592","authenticated-orcid":false,"given":"Stefan","family":"Habringer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten O.","family":"Goetze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke","family":"J\u00e4ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Georg","family":"Rammensee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6719-1847","authenticated-orcid":false,"given":"Helmut R.","family":"Salih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6404-7391","authenticated-orcid":false,"given":"Juliane S.","family":"Walz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,18]]},"reference":[{"key":"40758_CR1","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1056\/NEJMoa2105290","volume":"385","author":"AR Falsey","year":"2021","unstructured":"Falsey, A. R. et al. Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine. N. Engl. J. Med. 385, 2348\u20132360 (2021).","journal-title":"N. Engl. J. Med."},{"key":"40758_CR2","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 383, 2603\u20132615 (2020).","journal-title":"N. Engl. J. Med."},{"key":"40758_CR3","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403\u2013416 (2021).","journal-title":"N. Engl. J. Med."},{"key":"40758_CR4","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1056\/NEJMoa2107659","volume":"385","author":"PT Heath","year":"2021","unstructured":"Heath, P. T. et al. Safety and efficacy of NVX-CoV2373 Covid-19 Vaccine. N. Engl. J. Med. 385, 1172\u20131183 (2021).","journal-title":"N. Engl. J. Med."},{"key":"40758_CR5","doi-asserted-by":"publisher","first-page":"3165","DOI":"10.1182\/blood.2021011568","volume":"137","author":"Y Herishanu","year":"2021","unstructured":"Herishanu, Y. et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood 137, 3165\u20133173 (2021).","journal-title":"Blood"},{"key":"40758_CR6","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/S1470-2045(21)00213-8","volume":"22","author":"L Monin","year":"2021","unstructured":"Monin, L. et al. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. Lancet Oncol. 22, 765\u2013778 (2021).","journal-title":"Lancet Oncol."},{"key":"40758_CR7","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.ccell.2021.06.002","volume":"39","author":"A Thakkar","year":"2021","unstructured":"Thakkar, A. et al. Seroconversion rates following COVID-19 vaccination among patients with cancer. Cancer Cell 39, 1081\u20131090.e1082 (2021).","journal-title":"Cancer Cell"},{"key":"40758_CR8","doi-asserted-by":"publisher","first-page":"2703","DOI":"10.1038\/s41375-021-01270-w","volume":"35","author":"LE Roeker","year":"2021","unstructured":"Roeker, L. E. et al. COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia. Leukemia 35, 2703\u20132705 (2021).","journal-title":"Leukemia"},{"key":"40758_CR9","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41590-020-00808-x","volume":"22","author":"A Nelde","year":"2021","unstructured":"Nelde, A. et al. SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition. Nat. Immunol. 22, 74\u201385 (2021).","journal-title":"Nat. Immunol."},{"key":"40758_CR10","doi-asserted-by":"publisher","unstructured":"Bilich, T. et al. T cell and antibody kinetics delineate SARS-CoV-2 peptides mediating long-term immune responses in COVID-19 convalescent individuals. Sci. Transl. Med. 13, https:\/\/doi.org\/10.1126\/scitranslmed.abf7517 (2021).","DOI":"10.1126\/scitranslmed.abf7517"},{"key":"40758_CR11","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.cell.2020.11.029","volume":"184","author":"LB Rodda","year":"2021","unstructured":"Rodda, L. B. et al. Functional SARS-CoV-2-specific immune memory persists after mild COVID-19. Cell 184, 169\u2013183 e117 (2021).","journal-title":"Cell"},{"key":"40758_CR12","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1038\/s41591-020-0965-6","volume":"26","author":"QX Long","year":"2020","unstructured":"Long, Q. X. et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat. Med. 26, 1200\u20131204 (2020).","journal-title":"Nat. Med."},{"key":"40758_CR13","doi-asserted-by":"publisher","unstructured":"Tan, A. T. et al. Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients. Cell Rep. 34, https:\/\/doi.org\/10.1016\/j.celrep.2021.108728 (2021).","DOI":"10.1016\/j.celrep.2021.108728"},{"key":"40758_CR14","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1111\/pai.13263","volume":"31","author":"A Soresina","year":"2020","unstructured":"Soresina, A. et al. Two X-linked agammaglobulinemia patients develop pneumonia as COVID-19 manifestation but recover. Pediatr. Allergy Immunol. 31, 565\u2013569 (2020).","journal-title":"Pediatr. Allergy Immunol."},{"key":"40758_CR15","doi-asserted-by":"publisher","unstructured":"Dan, J. M. et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science eabf4063, https:\/\/doi.org\/10.1126\/science.abf4063 (2021).","DOI":"10.1126\/science.abf4063"},{"key":"40758_CR16","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-020-2598-9","volume":"587","author":"J Braun","year":"2020","unstructured":"Braun, J. et al. SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19. Nature 587, 270\u2013274 (2020).","journal-title":"Nature"},{"key":"40758_CR17","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1038\/s41586-021-04232-5","volume":"601","author":"JS Heitmann","year":"2022","unstructured":"Heitmann, J. S. et al. A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity. Nature 601, 617\u2013622 (2022).","journal-title":"Nature"},{"key":"40758_CR18","doi-asserted-by":"publisher","unstructured":"Bilich, T. et al. Preexisting and post-COVID-19 immune responses to SARS-CoV-2 in cancer patients. Cancer Discov. https:\/\/doi.org\/10.1158\/2159-8290.CD-21-0191 (2021).","DOI":"10.1158\/2159-8290.CD-21-0191"},{"key":"40758_CR19","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jobb.2021.12.001","volume":"4","author":"Y Sun","year":"2022","unstructured":"Sun, Y., Lin, W., Dong, W. & Xu, J. Origin and evolutionary analysis of the SARS-CoV-2 Omicron variant. J. Biosaf. Biosecur. 4, 33\u201337 (2022).","journal-title":"J. Biosaf. Biosecur."},{"key":"40758_CR20","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1016\/S0140-6736(20)31187-9","volume":"395","author":"NM Kuderer","year":"2020","unstructured":"Kuderer, N. M. et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet 395, 1907\u20131918 (2020).","journal-title":"Lancet"},{"key":"40758_CR21","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1038\/s41591-020-0979-0","volume":"26","author":"EV Robilotti","year":"2020","unstructured":"Robilotti, E. V. et al. Determinants of COVID-19 disease severity in patients with cancer. Nat. Med. 26, 1218\u20131223 (2020).","journal-title":"Nat. Med."},{"key":"40758_CR22","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1158\/2159-8290.CD-20-0422","volume":"10","author":"M Dai","year":"2020","unstructured":"Dai, M. et al. Patients with cancer appear more vulnerable to SARS-COV-2: a multicenter study during the COVID-19 outbreak. Cancer Discov. 10, 783\u2013791 (2020).","journal-title":"Cancer Discov."},{"key":"40758_CR23","doi-asserted-by":"publisher","unstructured":"Wang, L., Kaelber, D. C., Xu, R. & Berger, N. A. COVID-19 breakthrough infections, hospitalizations and mortality in fully vaccinated patients with hematologic malignancies: a clarion call for maintaining mitigation and ramping-up research. Blood Rev. 100931, https:\/\/doi.org\/10.1016\/j.blre.2022.100931 (2022).","DOI":"10.1016\/j.blre.2022.100931"},{"key":"40758_CR24","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1038\/s41375-020-0959-x","volume":"34","author":"L Scarfo","year":"2020","unstructured":"Scarfo, L. et al. COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European research initiative on CLL, and CLL campus. Leukemia 34, 2354\u20132363 (2020).","journal-title":"Leukemia"},{"key":"40758_CR25","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1046\/j.1525-1497.1998.00031.x","volume":"13","author":"AC Jung","year":"1998","unstructured":"Jung, A. C. & Paauw, D. S. Diagnosing HIV-related disease: using the CD4 count as a guide. J. Gen. Intern. Med. 13, 131\u2013136 (1998).","journal-title":"J. Gen. Intern. Med."},{"key":"40758_CR26","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1586\/14760584.1.1.111","volume":"1","author":"J Aucouturier","year":"2002","unstructured":"Aucouturier, J., Dupuis, L., Deville, S., Ascarateil, S. & Ganne, V. Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines. Expert Rev. Vaccines 1, 111\u2013118 (2002).","journal-title":"Expert Rev. Vaccines"},{"key":"40758_CR27","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1080\/21645515.2015.1071455","volume":"12","author":"E van Doorn","year":"2016","unstructured":"van Doorn, E., Liu, H., Huckriede, A. & Hak, E. Safety and tolerability evaluation of the use of Montanide ISA51 as vaccine adjuvant: a systematic review. Hum. Vaccin Immunother. 12, 159\u2013169 (2016).","journal-title":"Hum. Vaccin Immunother."},{"key":"40758_CR28","doi-asserted-by":"publisher","unstructured":"Rammensee, H. G. et al. A new synthetic toll-like receptor 1\/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer. J. Immunother. Cancer 7, https:\/\/doi.org\/10.1186\/s40425-019-0796-5 (2019).","DOI":"10.1186\/s40425-019-0796-5"},{"key":"40758_CR29","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1038\/s41564-020-00789-5","volume":"5","author":"WS Lee","year":"2020","unstructured":"Lee, W. S., Wheatley, A. K., Kent, S. J. & DeKosky, B. J. Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies. Nat. Microbiol. 5, 1185\u20131191 (2020).","journal-title":"Nat. Microbiol."},{"key":"40758_CR30","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1093\/gerona\/glab206","volume":"77","author":"A Garcia-Torre","year":"2022","unstructured":"Garcia-Torre, A. et al. Surviving older patients show preserved cellular and humoral immunological memory several months after SARS-CoV-2 infection. J. Gerontol. A Biol. Sci. Med. Sci. 77, 33\u201340 (2022).","journal-title":"J. Gerontol. A Biol. Sci. Med. Sci."},{"key":"40758_CR31","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1126\/science.1076064","volume":"298","author":"I Messaoudi","year":"2002","unstructured":"Messaoudi, I., Guevara Patino, J. A., Dyall, R., LeMaoult, J. & Nikolich-Zugich, J. Direct link between mhc polymorphism, T cell avidity, and diversity in immune defense. Science 298, 1797\u20131800 (2002).","journal-title":"Science"},{"key":"40758_CR32","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/nm1520","volume":"13","author":"P Kiepiela","year":"2007","unstructured":"Kiepiela, P. et al. CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat. Med. 13, 46\u201353 (2007).","journal-title":"Nat. Med."},{"key":"40758_CR33","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa2119451","volume":"386","author":"N Andrews","year":"2022","unstructured":"Andrews, N. et al. Covid-19 vaccine effectiveness against the Omicron (B.1.1.529) variant. N. Engl. J. Med. 386, 1532\u20131546 (2022).","journal-title":"N. Engl. J. Med."},{"key":"40758_CR34","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/s41586-022-04594-4","volume":"604","author":"S Iketani","year":"2022","unstructured":"Iketani, S. et al. Antibody evasion properties of SARS-CoV-2 Omicron sublineages. Nature 604, 553\u2013556 (2022).","journal-title":"Nature"},{"key":"40758_CR35","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1016\/S0140-6736(20)32466-1","volume":"396","author":"MN Ramasamy","year":"2021","unstructured":"Ramasamy, M. N. et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2\/3 trial. Lancet 396, 1979\u20131993 (2021).","journal-title":"Lancet"},{"key":"40758_CR36","doi-asserted-by":"publisher","first-page":"233","DOI":"10.18176\/jiaci.0069","volume":"26","author":"G Azizi","year":"2016","unstructured":"Azizi, G. et al. T-Cell abnormalities in common variable immunodeficiency. J. Investig. Allergol. Clin. Immunol. 26, 233\u2013243 (2016).","journal-title":"J. Investig. Allergol. Clin. Immunol."},{"key":"40758_CR37","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1111\/j.1365-2249.2011.04377.x","volume":"164","author":"H Martini","year":"2011","unstructured":"Martini, H. et al. Importance of B cell co-stimulation in CD4(+) T cell differentiation: X-linked agammaglobulinaemia, a human model. Clin. Exp. Immunol. 164, 381\u2013387 (2011).","journal-title":"Clin. Exp. Immunol."},{"key":"40758_CR38","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1126\/science.abe1107","volume":"370","author":"KW Ng","year":"2020","unstructured":"Ng, K. W. et al. Preexisting and de novo humoral immunity to SARS-CoV-2 in humans. Science 370, 1339\u20131343 (2020).","journal-title":"Science"},{"key":"40758_CR39","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1126\/science.1082305","volume":"300","author":"DJ Shedlock","year":"2003","unstructured":"Shedlock, D. J. & Shen, H. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 300, 337\u2013339 (2003).","journal-title":"Science"},{"key":"40758_CR40","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.4049\/jimmunol.179.2.1113","volume":"179","author":"CC Kemball","year":"2007","unstructured":"Kemball, C. C. et al. The antiviral CD8+ T cell response is differentially dependent on CD4+ T cell help over the course of persistent infection. J. Immunol. 179, 1113\u20131121 (2007).","journal-title":"J. Immunol."},{"key":"40758_CR41","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.coi.2008.03.007","volume":"20","author":"PJ van de Berg","year":"2008","unstructured":"van de Berg, P. J., van Leeuwen, E. M., ten Berge, I. J. & van Lier, R. Cytotoxic human CD4(+) T cells. Curr. Opin. Immunol. 20, 339\u2013343 (2008).","journal-title":"Curr. Opin. Immunol."},{"key":"40758_CR42","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1084\/jem.172.5.1353","volume":"172","author":"M Tsuji","year":"1990","unstructured":"Tsuji, M., Romero, P., Nussenzweig, R. S. & Zavala, F. CD4+ cytolytic T cell clone confers protection against murine malaria. J. Exp. Med. 172, 1353\u20131357 (1990).","journal-title":"J. Exp. Med."},{"key":"40758_CR43","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1158\/2643-3230.BCD-22-0077","volume":"3","author":"LM Greenberger","year":"2022","unstructured":"Greenberger, L. M. et al. Anti-spike T-cell and antibody responses to SARS-CoV-2 mRNA vaccines in patients with hematologic malignancies. Blood Cancer Discov. 3, 481\u2013489 (2022).","journal-title":"Blood Cancer Discov."},{"key":"40758_CR44","doi-asserted-by":"publisher","first-page":"1035344","DOI":"10.3389\/fimmu.2022.1035344","volume":"13","author":"SPA Hernandez","year":"2022","unstructured":"Hernandez, S. P. A. et al. Three doses of BNT162b2 COVID-19 mRNA vaccine establish long-lasting CD8(+) T cell immunity in CLL and MDS patients. Front. Immunol. 13, 1035344 (2022).","journal-title":"Front. Immunol."},{"key":"40758_CR45","doi-asserted-by":"publisher","unstructured":"Gallais, F. et al. Intrafamilial Exposure to SARS-CoV-2 associated with cellular immune response without Seroconversion, France. Emerg. Infect. Dis. 27, https:\/\/doi.org\/10.3201\/eid2701.203611 (2021).","DOI":"10.3201\/eid2701.203611"},{"key":"40758_CR46","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s40259-021-00511-9","volume":"36","author":"A Volk","year":"2022","unstructured":"Volk, A. et al. SARS-CoV-2 neutralization in convalescent plasma and commercial lots of plasma-derived immunoglobulin. BioDrugs 36, 41\u201353 (2022).","journal-title":"BioDrugs"},{"key":"40758_CR47","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1056\/NEJMoa2109682","volume":"385","author":"MP O\u2019Brien","year":"2021","unstructured":"O\u2019Brien, M. P. et al. Subcutaneous REGEN-COV antibody combination to prevent Covid-19. N. Engl. J. Med 385, 1184\u20131195 (2021).","journal-title":"N. Engl. J. Med"},{"key":"40758_CR48","doi-asserted-by":"publisher","unstructured":"Rammensee, H. G. et al. Designing a SARS-CoV-2 T-Cell-inducing vaccine for high-risk patient groups. Vaccines 9, https:\/\/doi.org\/10.3390\/vaccines9050428 (2021).","DOI":"10.3390\/vaccines9050428"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-40758-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-40758-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-40758-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T02:04:11Z","timestamp":1700186651000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-40758-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,18]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["40758"],"URL":"https:\/\/doi.org\/10.1038\/s41467-023-40758-0","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,18]]},"assertion":[{"value":"14 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.S.H., H.R.S., A.N., H.-G.R. and J.S.W. are listed as inventors on a patent related to the SARS-CoV-2 T-cell epitopes included in CoVac-1. H.-G.R. and K.-H.W. are listed as inventor on a patent related to the adjuvant XS15 included in CoVac-1. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5032"}}